These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 19717477)
21. Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp. Garau J; Fritsch A; Arvis P; Read RC J Chemother; 2010 Aug; 22(4):264-6. PubMed ID: 20685631 [TBL] [Abstract][Full Text] [Related]
22. Pulmonary tuberculosis among patients hospitalised with community-acquired pneumonia in a tuberculosis-prevalent area. Chon SB; Kim TS; Oh WS; Lee SJ; Han SS; Kim WJ Int J Tuberc Lung Dis; 2013 Dec; 17(12):1626-31. PubMed ID: 24200280 [TBL] [Abstract][Full Text] [Related]
23. Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment Outcomes. Kang YA; Shim TS; Koh WJ; Lee SH; Lee CH; Choi JC; Lee JH; Jang SH; Yoo KH; Jung KH; Kim KU; Choi SB; Ryu YJ; Kim KC; Um S; Kwon YS; Kim YH; Choi WI; Jeon K; Hwang YI; Kim SJ; Lee HK; Heo E; Yim JJ Ann Am Thorac Soc; 2016 Mar; 13(3):364-70. PubMed ID: 26871879 [TBL] [Abstract][Full Text] [Related]
24. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E; Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092 [TBL] [Abstract][Full Text] [Related]
25. Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity. Singh A Clin Infect Dis; 2007 Jul; 45(1):133; author reply 134-5. PubMed ID: 17554716 [No Abstract] [Full Text] [Related]
26. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia. Lode H; Magyar P; Muir JF; Loos U; Kleutgens K; Clin Microbiol Infect; 2004 Jun; 10(6):512-20. PubMed ID: 15191378 [TBL] [Abstract][Full Text] [Related]
27. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. el Moussaoui R; de Borgie CA; van den Broek P; Hustinx WN; Bresser P; van den Berk GE; Poley JW; van den Berg B; Krouwels FH; Bonten MJ; Weenink C; Bossuyt PM; Speelman P; Opmeer BC; Prins JM BMJ; 2006 Jun; 332(7554):1355. PubMed ID: 16763247 [TBL] [Abstract][Full Text] [Related]
28. [Role of moxifloxacin in the treatment of community-acquired pneumonia]. Máthé A; Tóth K; Kovács G Orv Hetil; 2004 Oct; 145(44):2227-30. PubMed ID: 15626167 [TBL] [Abstract][Full Text] [Related]
30. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Dorman SE; Johnson JL; Goldberg S; Muzanye G; Padayatchi N; Bozeman L; Heilig CM; Bernardo J; Choudhri S; Grosset JH; Guy E; Guyadeen P; Leus MC; Maltas G; Menzies D; Nuermberger EL; Villarino M; Vernon A; Chaisson RE; Am J Respir Crit Care Med; 2009 Aug; 180(3):273-80. PubMed ID: 19406981 [TBL] [Abstract][Full Text] [Related]
31. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Yoon YS; Lee HJ; Yoon HI; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ Int J Tuberc Lung Dis; 2005 Nov; 9(11):1215-9. PubMed ID: 16333927 [TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors. Sun T; Sun L; Wang R; Ren X; Sui DJ; Pu C; Ren Y; Liu Y; Yang Z; Li F Chin Med J (Engl); 2014; 127(7):1201-5. PubMed ID: 24709166 [TBL] [Abstract][Full Text] [Related]
33. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC; Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication. Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781 [TBL] [Abstract][Full Text] [Related]
35. Acceptability of sputum specimens for diagnosing pulmonary tuberculosis. Lee YJ; Shin S; Roh EY; Yoon JH; Kim DK; Chung HS; Lee CH J Korean Med Sci; 2015 Jun; 30(6):733-6. PubMed ID: 26028925 [TBL] [Abstract][Full Text] [Related]
36. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. API Consensus Expert Committee J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350 [TBL] [Abstract][Full Text] [Related]
37. Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community. Jeon CY; Calver AD; Victor TC; Warren RM; Shin SS; Murray MB Int J Tuberc Lung Dis; 2011 Jan; 15(1):77-83. PubMed ID: 21276301 [TBL] [Abstract][Full Text] [Related]
38. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866 [TBL] [Abstract][Full Text] [Related]
39. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Johnson JL; Hadad DJ; Boom WH; Daley CL; Peloquin CA; Eisenach KD; Jankus DD; Debanne SM; Charlebois ED; Maciel E; Palaci M; Dietze R Int J Tuberc Lung Dis; 2006 Jun; 10(6):605-12. PubMed ID: 16776446 [TBL] [Abstract][Full Text] [Related]
40. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]